The First Affiliated Hospital of Xinxiang Medical College
People's Republic of China
- Country
- People's Republic of China
- Ownership
- Private
- Established
- 1950-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.gy120.net/
A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of Oral Teslanbaicin in Patients With Radiation Proctitis
Phase 1
- Conditions
- Safety
- Interventions
- Drug: A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of Oral Tesilanbaiju in Patients with Radiation ProctitisDrug: Teslanbai oral therapy
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Target Recruit Count
- 29
- Registration Number
- NCT06974123
- Locations
- 🇨🇳
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China
Colorectal Cancer Screening in Xinxiang City
Completed
- Conditions
- Colorectal Cancer
- First Posted Date
- 2025-01-21
- Last Posted Date
- 2025-01-21
- Target Recruit Count
- 25000
- Registration Number
- NCT06785714
- Locations
- 🇨🇳
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China
Current Status of Diagnosis and Treatment of Uroepithelial Carcinoma
Not yet recruiting
- Conditions
- Uroepithelial Carcinoma
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Target Recruit Count
- 400
- Registration Number
- NCT06663735
- Locations
- 🇨🇳
Kaifeng City Center Hospital, Kaifeng, Henan, China
🇨🇳Luoyang Renda Hospital, Luoyang, Henan, China
🇨🇳Nanyang City Center Hospital, Nanyang, Henan, China
Current Survey on Chemotherapy-Related Myelosuppression and Clinical Management in Chinese County-level Tumor Patients
Not yet recruiting
- Conditions
- Myelosuppression
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-16
- Target Recruit Count
- 1000
- Registration Number
- NCT06641934
- Locations
- 🇨🇳
The First Affiliated Hospital of Xinxiang Medical College, Xinxiang, Henan, China
Pharmacovigilance Assessment of Reporting of Cardiovascular Adverse Events With Antineoplastic Agents (PARCA)
Not yet recruiting
- Conditions
- Cardiac DiseasesCancerVascular DiseasesCardiovascular Diseases
- Interventions
- Drug: Antineoplastic Agents
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-05-10
- Target Recruit Count
- 800000
- Registration Number
- NCT06409481
Recombinant Human Endostatin Combined With Envafolimab and Synchronal Radiochemotherapy
Phase 2
Not yet recruiting
- Conditions
- Locally Advanced Squamous Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Target Recruit Count
- 30
- Registration Number
- NCT06279754
the Efficacy and Safety of Ondansetron Oral Soluble Pellicles
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Target Recruit Count
- 184
- Registration Number
- NCT06282211
- Locations
- 🇨🇳
Keya Zhi, Weihui, None Selected, China
Trilaciclib Combined With Chemotherapy for Perioperative Treatment of Osteosarcoma
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-01-22
- Target Recruit Count
- 20
- Registration Number
- NCT06217003
- Locations
- 🇨🇳
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China
Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy
Phase 2
Not yet recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-12-27
- Last Posted Date
- 2023-12-27
- Target Recruit Count
- 35
- Registration Number
- NCT06182800
the Safety and Efficacy of Intravitreal Injection of Tpdelansbsalbac in Malignant Effusions.
Not Applicable
Recruiting
- Conditions
- Salmonella Bacteremia
- Interventions
- Biological: Tpdelansbsalbac
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2024-01-29
- Target Recruit Count
- 65
- Registration Number
- NCT06178003
- Locations
- 🇨🇳
The First Affiliated Hospital of Xinxiang Medical university, Henan Province, China
© Copyright 2025. All Rights Reserved by MedPath